swenu031471501

мужчина
Социальные ссылки
Bio
After four months of treatment with Letrozole, 11 out of 15 men experienced improvement in either their sperm concentration or motility. For the KKH study, researchers recruited men with low sperm count of unknown cause regardless of their T/E ratios. However, the frequency of this ratio is not as prevalent in our clinical practice," shares primary investigator Dr Liu Shuling, Consultant, Department of Reproductive Medicine, KKH.
Letrozole is also approved for the treatment of post-menopausal female breast cancer patients that are exhibiting symptoms of Estrogen receptor unknown breast cancer. It is also approved for the extended treatment for post-menopausal female breast cancer patients after 5 years of Nolvadex administration. Letro is approved by the FDA for the treatment of post-menopausal female breast cancer patients as an adjunctive treatment when first-line treatments (such as Nolvadex) have failed to work. The T + AI combination implant seems to be a promising therapy that has the potential to simultaneously treat breast cancer, prevent side effects of chemotherapy, and improve health and quality of life in breast cancer survivors. This case report also supports previous data on the safety and efficacy of the combination T + AI on quality of life in breast cancer survivors.6 These preliminary findings may stimulate interest in further research on the prevention of chemotherapy-induced toxicities, and also the treatment of menopausal symptoms in millions of breast cancer survivors worldwide.
A case study describes a morbidly obese infertile man, who after a similar treatment with anastrozole showed a normalized pituitary-testis axis, spermatogenesis and fertility . Finally, the decreased levels of estradiol may have affected the expected rise in lean body mass . A small, controlled study demonstrated that anastrozole in a dose of 1 mg daily during 12 weeks will result in doubling of the mean bioavailable testosterone level in older men . Therefore aromatase inhibitors have been tested in older men suffering from so-called late-onset hypogonadism or partial androgen deficiency. Due to their mode of action the use of aromatase inhibitors is limited to men with at least some residual function of the hypothalamo-pituitary-gonadal axis.
The investigators were unable to reach the study’s primary end point, but they demonstrated a significant increase in lean body mass, testosterone and estradiol. In a randomized, double blinded study the researchers demonstrated that clomiphene resulted in significantly higher testosterone levels than anastrozole (28). This highlights the fundamental difference between AIs vs. exogenous testosterone, as the latter will cause a rise in both estradiol and testosterone levels. In this study, the authors confirmed increases in testosterone but failed to reach any of their other clinical endpoints.
These authors used ammonium sulfate precipitation to measure bioavailable estradiol levels whereas if they had calculated bioavailable estradiol levels using the popular Sodergard equation 79,80 their proposed threshold may have been as high as 75 pM. Thresholds should be interpreted with great caution because they rely heavily on the methods used to measure total or bioavailable estradiol levels. Aromatase inhibitors are widely prescribed for hormone-responsive breast carcinoma in postmenopausal women. The combination of testosterone and letrozole, therefore, was tested in boys with constitutional delay of puberty.
https://tovegans.tube/@lachlanseward7?page=about

Просмотр музыки

хранить

Ваша музыка

swenu031471501

Следующий

Исполнители, чтобы следовать

Лучшие треки за неделю

Очередь